Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
N.ZaneteP
SPL UNCLASSIFIED SECTION Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
You may eat 30-40% fewer calories without losing pounds immediately because your body continues burning through stored energy reserves
Beyond scheduled exercise, simply increasing your physical activity through small changes , like walking more and sitting less day-to-day, can help support weight loss
They make sure the compounded drug has the right, approved active ingredient
Meta-analysis of the association between new hypoglycemic agents and digestive diseases
US$ 20.26
US$ 21.99
US$ 28.88
